Utomilumab

N/A

Report date: 2024/02/21 14:40:17

Base Information

Drug NameUtomilumab
Drug Alias NamePF-5082566PF-2566PF-05082566
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonists
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsBone metastasesSolid tumoursProstatic Neoplasms, Castration-Resistant +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesArray BiopharmaPfizer IncNational Cancer Institute +[4] 
Inactive CompaniesKite Pharma
Active IndicationsBone metastasesSolid tumoursProstatic Neoplasms, Castration-Resistant +[14] 
Inactive IndicationsOropharyngeal NeoplasmsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[7] 

Other Information

ATC CodeN/A
Related LinksWikipedia